Kane Biotech signs with U.S. gov't distributor

Executive Summary

• Kane Biotech Inc. has entered into a strategic distribution partnership with Marathon Medical Corp., a federally verified service-disabled veteran-owned small business (SDVOSB), to expand its U.S. commercial footprint.
• The partnership provides Kane Biotech with access to established U.S. government-authorized purchasing pathways, specifically targeting the Veterans Affairs (VA), Department of Defense (DOD), and Indian Health Services (IHS) markets for its revyve anti-microbial wound care portfolio.
• Concurrently, the company is building a contract-based sales team with representatives across the U.S., with plans to continue expanding this group throughout 2026.

Key Details

• Distribution Partner: Marathon Medical Corp., a leading nationwide medical supply distributor and SDVOSB.
• Target Markets: U.S. Veterans Affairs (VA), U.S. Department of Defense (DOD), and U.S. Indian Health Services (IHS).
• Product Portfolio: The partnership supports the commercialization of the revyve anti-microbial wound gel, revyve anti-microbial wound gel spray, and revyve anti-microbial skin and wound cleanser.
• Regulatory Status: revyve products are U.S. FDA 510(k) cleared and Health Canada approved.
• Sales Strategy: Kane Biotech is establishing a contract-based sales team with members located across the U.S.
• Timeline: The sales team expansion is scheduled to continue throughout 2026.
• Strategic Benefit: The partnership streamlines procurement, logistics, and product onboarding for the revyve wound care line within the federal health care supply chain.

Notable Quotes

• "We are continuing to strategically build the commercial infrastructure required to make revyve a national brand in advanced wound care. Our new contract-based sales agents expand our reach into key markets, while our partnership with Marathon Medical, gives us a powerful foothold within the U.S. government system -- an essential step in making revyve accessible to the veterans, active service members and indigenous peoples." — Dr. Robert Huizinga, Interim Chief Executive Officer